top of page
MigVax is developing an oral COVID-19 sub-unit vaccine. 

MigVax, an affiliate of The Migal Galilee Research Institute, is a startup developing Migvax-101, a novel oral subunit COVID-19 vaccine that has demonstrated effectivity in pre-clinical tests as a booster for previously vaccinated persons.


CEPI Log.jpg
CEPI announces first funding awards to MigVax in quest to develop broadly protective coronavirus vaccines (read more)
MigVax and OurCrowd raises $12M for its COVID-19 vaccine efforts
Download a Mutual Press Release by MigVax and OurCrowd
MigVax team develop Covid-19 vaccine
Meet the Multidisciplinary MigVax Team
QA Leader in Protein Biochemistry for COVID 19 Vaccine
bottom of page